- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 13.11. | Marinus cuts 45% of staff as seizure med Ztalmy remains in limbo following phase 3 misses | ||
| 13.11. | After election, FDA's Califf lays out hopes for his Trump-appointed successor | ||
| 13.11. | BMS, Merck, Amgen and more must look to M&A to offset looming patent lapses: Leerink | ||
| 13.11. | AstraZeneca and Merck's Koselugo delivers phase 3 trial win in adults with NF1, teeing up filings | ||
| 12.11. | Bayer's rising prostate cancer star Nubeqa crosses blockbuster barrier as Xarelto continues downward descent | ||
| 12.11. | FDA rejects Intercept's ask for Ocaliva full nod in rare liver disease, but accelerated approval remains | ||
| 12.11. | Pfizer explores sale of hospital drugs unit amid activist investor's call for accountability: Reuters | ||
| 12.11. | StrideMD touts remote patient monitoring tech in National Diabetes Month awareness campaign | ||
| 12.11. | With high hopes for the economy, AstraZeneca adds $2B to US investment in manufacturing, R&D | ||
| 12.11. | Swiss CDMO Lonza to double its ADC prowess by adding 2 suites, 200 jobs at its Visp site | ||
| 12.11. | AstraZeneca CEO defends corporate oversight, $80B revenue target amid China probes | ||
| 12.11. | PhRMA TV spot calls on lame-duck Congress to pass PBM reforms, secure savings for patients | ||
| 12.11. | Assertio fires back at activist investor's 'baseless allegations' over Rolvedon | ||
| 12.11. | GSK, with survey highlighting challenges facing gynecological cancer patients, kicks off initiative to close gaps in care | ||
| 11.11. | Thermo Fisher charts 160 layoffs in Massachusetts amid viral vector overhaul | ||
| 11.11. | Humira, Cosentyx gaining favor as treatments for hidradenitis suppurativa, but more support for biologics needed: Spherix | ||
| 11.11. | Autolus readies its CAR-T Aucatzyl to go after heavy hitter competition following FDA nod | ||
| 11.11. | MSF calls on Lilly, Novo and Sanofi to cut insulin pen prices to $1 | ||
| 11.11. | With China ties under US scrutiny, GenScript goes Down Under with new facility | ||
| 11.11. | With US launch progressing, ARS inks another licensing deal for epinephrine spray Neffy worth up to $465M | ||
| 08.11. | GSK calls it quits on trade group BIO for 2025, following exits by Takeda, UCB and more | ||
| 08.11. | AstraZeneca, Amgen's Tezspire scores in rhinosinusitis study | ||
| 08.11. | Daiichi Sankyo links up with Korea's Alteogen on subcutaneous Enhertu in $300M licensing deal | ||
| 08.11. | Investment fund Oaktree calls for board shakeup at Indivior, accusing company of 'value destruction' | ||
| 08.11. | FDA proposes ban on main ingredient in many OTC decongestants |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
